[Clinical trial of febuprol, a new substance with choleretic activity. Study of efficacy and tolerability].
In a clinical trial, performed according to new criteria of the AMG (Arzneimittelgesetz) 1976, a new choleretic monosubstance 3-n-butoxy-1-phenoxy-2-propanol (code number: K 10.033, H 33, febuprol, Valbil) has been tested. The clinical investigations conducted on 712 healthy volunteers and patients within a period of 4 years showed that Valbil is an effective and safe drug. Besides the choleretic properties, febuprol has some additional spasmolytic and lipid lowering effects.